FDA issues healthcare professional alert-increased botox injury warning label.
New York, NY(NewYorkInjuryNews.com)–The U.S. Food and Drug Administration (FDA) www.fda.gov notified healthcare professionals nationwide on Thursday that Botox manufacturers must strengthen product injury warnings. The FDA is requiring licensed manufacturers of botulinum toxin products (Botox) to place a boxed warning label stating the risk of adverse events when using Botox.
The FDA received numerous reports of adverse events and harmful side effects after localized administration of botulinum toxin products. The effects of the toxin spread beyond the injected administration site and injured patients and cosmetic consumers. According to Wikipedia www.wikipedia.org, botulinum toxin also marketed and sold under the brand names; Botox, Dysport, Myobloc, Neurobloc, Xeomin, Botox Cosmetic and Vistabel, is a medication and a neurotoxic protein produced by the bacterium Clostridium botulinum. It is the most toxic protein known. Doctors and nurses throughout the world use botulinum toxin to treat muscle spasms. It is sold commercially for cosmetic treatment.
NewYorkInjuryNews.com news for New York product injury lawyers.
